Bayer Notches Dual EYLEA 8mg Wins With China nAMD Approval and EU 6-Month Interval Extension
High-dose aflibercept secured a regulatory victory in China as 6-month dosing nears European approval Good news apparently comes in twos…
Faricimab – The Fight Against Retinal Diseases
Faricimab (Vabysmo) is the first approved bispecific antibody uniquely engineered to block two key pathways driving retinal vascular disease by…
latest posts
